Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UpHealth Q4 EPS $(1.82) May Not Be Comparable To $(0.82) Estimate, Sales $40.50M Beat $39.77M Estimate

UpHealth (NYSE:UPH) reported quarterly losses of $(1.82) per share which missed the analyst consensus estimate of $(0.82) by 121.95 percent. This is a 92.3 percent increase over losses of $(23.64) per share from the same
byBenzinga Newsdesk
March 2, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

UpHealth (NYSE:UPH) reported quarterly losses of $(1.82) per share which missed the analyst consensus estimate of $(0.82) by 121.95 percent. This is a 92.3 percent increase over losses of $(23.64) per share from the same period last year. The company reported quarterly sales of $40.50 million which beat the analyst consensus estimate of $39.77 million by 1.83 percent. This is a 19.44 percent increase over sales of $33.91 million the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Hemp-Focused Wellness Co. Moves Closer To Profitability, Reports Flat 2023 Revenue, Increase In Gross Profit

By Jelena Martinovic
March 28, 12:04 PM
Hemp-focused consumer wellness company CV Sciences, Inc. (OTCQB: CVSI) announced on Thursday its financial results for the year ended Dec. 31, 2023. The San Diego-based company reported a gross margin of 44.3% for fiscal year 2023, representing an improvement from 34.2% for 2022. For the fourth quarter gross margin was 45.8%, representing a sequential improvement from 45.1% in the third quarter. "Our 2023 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow," Joseph Dowling, CEO of CV Sciences, said. "As the CBD category consolidates, we have increased our market share in key sales channels, including the natural product retail channel. We will continue to focus our resources on new product development, as evidenced by our pet line expansion with our recent launch of pet chews for hip and joint health and calming care."

CVSI